These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27311868)

  • 1. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
    Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
    Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
    Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
    Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
    Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
    Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
    Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
    Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
    Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
    Grindheim JM; Nicetto D; Donahue G; Zaret KS
    Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
    Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
    Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.
    Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP
    Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.
    Vékony H; Raaphorst FM; Otte AP; van Lohuizen M; Leemans CR; van der Waal I; Bloemena E
    J Clin Pathol; 2008 Jun; 61(6):744-9. PubMed ID: 18326020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions.
    Xu J; Shao Z; Li D; Xie H; Kim W; Huang J; Taylor JE; Pinello L; Glass K; Jaffe JD; Yuan GC; Orkin SH
    Mol Cell; 2015 Jan; 57(2):304-316. PubMed ID: 25578878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
    Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
    Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
    Tian X; Pelton A; Shahsafaei A; Dorfman DM
    Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
    Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
    Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
    Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
    Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
    Tian X; Xu J; Dorfman DM
    Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.